Corticosteroid-Induced Hyperglycemia Mechanisms

Introduction to Hyperglycemia Mechanisms

Corticosteroids cause hyperglycemia through multiple mechanisms, including deterioration of insulin secretion, increased insulin resistance, and enhanced hepatic gluconeogenesis, as noted by the American College of Clinical Endocrinologists 1, 2

Corticosteroids alter carbohydrate metabolism through three main mechanisms: deterioration of insulin secretion by pancreatic beta cells, increased insulin resistance in peripheral tissues, and increased hepatic gluconeogenesis, according to the American Diabetes Association 3, 1
The insulin resistance induced by corticosteroids leads to increased release of free fatty acids from peripheral tissues, potentially harming the myocardium and altering protein metabolism, resulting in increased protein catabolism and delayed wound healing, as reported by the American Society of Anesthesiologists 4

Corticosteroids stimulate endogenous glucose production and may decrease glucose clearance, as stated by the American Society of Anesthesiologists 4
They increase renal glucose reabsorption, contributing to hyperglycemia, according to the American Society of Anesthesiologists 4
Corticosteroids promote lipolysis with release of free fatty acids, exacerbating insulin resistance, as noted by the American Diabetes Association 5, 4

The hyperglycemic effect typically peaks 7-9 hours after corticosteroid administration, as reported by the Journal for ImmunoTherapy of Cancer 3, 1
Prednisone administered in the morning usually produces a peak of hyperglycemia and insulin resistance approximately 8 hours after the dose, corresponding to elevations in glucose levels at mid-morning and afternoon, according to the Journal for ImmunoTherapy of Cancer 3, 6

The degree of hyperglycemia correlates directly with the corticosteroid dose, as noted by the Journal for ImmunoTherapy of Cancer 3, 1
Pre-existing diabetes significantly increases the risk of corticosteroid-induced hyperglycemia, as stated by the American College of Clinical Endocrinologists 1
Advanced age is a significant risk factor for developing hyperglycemia with corticosteroid use, according to the American Diabetes Association 5

Corticosteroid-induced hyperglycemia can cause osmotic diuresis leading to hypovolemia, decreased glomerular filtration rate, and prerenal azotemia, as reported by the American Diabetes Association 5
It affects leukocyte function, including decreased phagocytosis, impaired bacterial elimination, and chemotaxis, leading to hospital-acquired infections and poor wound healing, according to the American Diabetes Association 5
Acute hyperglycemia results in the activation of nuclear factor kappa B (NF-kB), production of pro-inflammatory cytokines, and oxidative stress, leading to increased vascular permeability and mitochondrial dysfunction, as noted by the American Diabetes Association 5
In severe cases, hyperosmolar hyperglycemic state, a potentially fatal condition, may develop, as reported by the Journal for ImmunoTherapy of Cancer and the American Diabetes Association 7, 8

The American College of Physicians recommends monitoring postprandial glucose (2 hours after lunch) rather than fasting glucose to capture the true hyperglycemic effect in patients on 5 mg prednisone daily, as fasting blood glucose measurements will miss the peak hyperglycemic effect and underestimate the severity 9, 10
For moderate-risk patients (those starting corticosteroids), the American Academy of Clinical Endocrinologists suggests checking serum glucose 2 hours postprandial or 8 hours after prednisone dosing at clinic visits 9, 10
The Endocrine Society recommends that high-risk patients (pre-existing diabetes) be provided with a glucometer for daily self-monitoring 9, 10
For mild hyperglycemia in diabetic patients, temporary adjustments to existing diabetes medications are usually sufficient, according to the American Diabetes Association 9, 10
The American Association of Clinical Endocrinologists notes that insulin therapy is rarely needed at this low dose unless glucose levels persistently exceed 200 mg/dL (11.1 mmol/L) 9, 10